Table 1.
Baseline characteristics
| Parameter | All patients | Idiopathic | SHD | Idiopathic vs. SHD, P-value |
|---|---|---|---|---|
| n = 24 | n = 12 | n = 12 | ||
| Age (years) | 57 ± 15 | 55 ± 17 | 61 ± 13 | 0.29 |
| Female sex, n (%) | 5 (21) | 3 (25) | 2 (17) | >0.99 |
| Body mass index (kg/m2) | 28 ± 4.9 | 26 ± 3 | 29 ± 6 | 0.31 |
| CHA2DS2VASc score, n (inter-quartile range) | 3 (0–3) | 1 (0–3) | 3 (3–4) | 0.01 |
| HAS-BLED score, n (inter-quartile range) | 1 (0–2) | 0 (0–1) | 1 (0–2) | 0.12 |
| LVEF, % (total range) | 47 ± 15 (23–74) | 61 ± 8 (47–74) | 36 ± 9 (23–50) | <0.001 |
| ICD present, n (%) | 12 (50) | 0 0 | 12 | <0.001 |
| Antiarrhythmic medication, n (%) | ||||
| Ajmalin | 1 (4) | 0 0 | 1 (8) | >0.99 |
| Flecainid | 1 (4) | 1 (8) | 0 0 | >0.99 |
| Propafenone | 0 0 | 0 0 | 0 0 | >0.99 |
| Amiodaron | 7 (29) | 1 (8) | 6 (50) | 0.07 |
| Sotalol | 0 0 | 0 0 | 0 0 | >0.99 |
| Mexilitine | 2 (8) | 0 0 | 2 (17) | 0.48 |
| Quinidine | 1 (4) | 0 0 | 1 (8) | >0.99 |
| Underlying condition, n (%) | ||||
| Post-myocarditis | 3 (13) | 0 0 | 3 (25) | 0.22 |
| Dilated cardiomyopathy | 6 (25) | 0 0 | 6 (50) | 0.01 |
| Ischaemic cardiomyopathy | 2 (8) | 0 0 | 2 (17) | 0.48 |
| Idiopathic | 12 (50) | 12 (50) | 0 0 | <0.001 |
| Sarcoidosis | 1 (4) | 0 0 | 1 (8) | >0.99 |
| Procedure indication, n (%) | ||||
| Recurrent PVC | 12/26 (46) | 9/12 (75) | 3/14 (21) | 0.02 |
| Recurrent VT | 12/26 (38) | 2/12 (17) | 10/14 (71) | 0.008 |
| VT storm | 2/26 (8) | 1/12 (8) | 1/14 (7) | >0.99 |
| Previous VA Ablation, n (%) | 22/26 (85) | 9/12 (75) | 13/14 (93) | 0.31 |
| No. of previous ablation, median (inter-quartile range) | 2 (1–2) | 1 (0–2) | 2 (1–3) | 0.01 |
Variables are expressed as absolute values, mean ± standard deviation, or median with inter-quartile ranges.
ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; PVC, premature ventricular contraction; SHD, structural heart disease; VA, ventricular arrhythmia; VT, ventricular tachycardia.